Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | KLF10 | Q13118 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL2209541 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL34268 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29528186 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2206798 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL649168 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL122111 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111302958-A | Preparation method of optically pure (R) -N-methyl-3-phenyl-3- (o-tolyloxy) -propylamine hydrochloride | 合肥医工医药股份有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-8299305-B2 | Method for preparing atomoxetine | SCI PHARMTECH, INC. (TW) | 2012-10-30 | — | — | US | claimed |
| US-20110319664-A1 | METHOD FOR PREPARING ATOMOXETINE | SCI PHARMTECH, INC. (TW) | 2011-12-29 | — | — | US | claimed |
| US-7485754-B2 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. (CA) | 2009-02-03 | — | — | US | claimed |
| US-20070270483-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYPROPYLAMINES | DIPHARMA FRANCIS S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1857435-A2 | A process for the preparation of aryloxypropylamines | Dipharma Francis S.r.l. (IT) | 2007-11-21 | — | — | EP | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| EP-1171417-B1 | METHODS FOR PREPARING 3-ARYLOXY-3-ARYLPROPYLAMINES AND INTERMEDIATES THEREOF | LILLY CO ELI (US) | 2005-11-09 | — | — | EP | claimed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | claimed |
| US-6541668-B1 | Using nucleophilic aromatic displacement in 1,3-dimethyl-2-imidazolidinone or N-methylpyrrolidinone | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | claimed |
| EP-1171417-A1 | METHODS FOR PREPARING 3-ARYLOXY-3-ARYLPROPYLAMINES AND INTERMEDIATES THEREOF | ELI LILLY AND COMPANY (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000061540-A1 | METHODS FOR PREPARING 3-ARYLOXY-3-ARYLPROPYLAMINES AND INTERMEDIATES THEREOF | ELI LILLY AND COMPANY (US) | 2000-10-19 | — | — | WO | claimed |
| EP-0193405-B1 | RACEMIZATION PROCESS | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| US-4777291-A | USING N-METHYL-3-(2-METHYLPHENOXY)-3-PHENYLPROPYLAMINE | ELI LILLY AND COMPANY (US) | 1988-10-11 | — | — | US | claimed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-0193405-A1 | Racemization process | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| EP-0052492-A1 | 3-Aryloxy-3-phenylpropylamines | ELI LILLY AND COMPANY (US) | 1982-05-26 | — | — | EP | claimed |
| JP-5070343-A | — | — | None | — | — | JP | disclosed |
| EP-0052492-A1 | 3-Aryloxy-3-phenylpropylamines | ELI LILLY AND COMPANY (US) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270483-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYPROPYLAMINES | NAT1, C1S, PAH | SLC6A2 104/4885SLC6A4 310/4885CYP1A2 22/4885 |
| US-20110319664-A1 | METHOD FOR PREPARING ATOMOXETINE | TPH2, HTR1A, HTR2B | SLC6A2 30/4885SLC6A4 43/4885CYP1A2 6/4885 |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A2 13/4885SLC6A4 1/4885CYP1A2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.